2026 - MS - Cyclin D1 in Histiocytic Neoplasms - Dongni Yi

In this scientific presentation from the Erdheim-Chester Disease Global Alliance (ECDGA), researcher Dongi presents laboratory findings on Cyclin D1 overexpression in histiocytic neoplasms and how it may create potential therapeutic vulnerabilities in diseases such as Erdheim-Chester Disease (ECD), Langerhans Cell Histiocytosis (LCH), Rosai-Dorfman Disease, and malignant histiocytosis. The presentation explores why Cyclin D1 is an important area of research in histiocytic neoplasms. While BRAF and MEK inhibitors are commonly used in the current treatment landscape, side effects and relapse after treatment interruption remain important challenges. This research focuses on whether Cyclin D1 overexpression may help identify new, more tolerable therapeutic strategies for patients with histiocytic disorders. This presentation covers important topics including: • Why new treatment approaches are needed in histiocytic neoplasms • The role of Cyclin D1 overexpression in cancer biology • How Cyclin D1 may serve as a hallmark and diagnostic marker in histiocytic neoplasms • How Cyclin D1 may contribute to cell cycle progression and DNA replication • The connection between Cyclin D1 overexpression and replication stress • How replication stress can lead to DNA damage and genomic instability • The role of ATR, ATM, and PARP pathways in DNA damage response • Laboratory models used to study Cyclin D1 overexpression • How Cyclin D1-overexpressing cells showed sensitivity to ATR and PARP inhibition • Early research findings suggesting possible future therapeutic strategies The talk also highlights both in vitro and in vivo research models, including cell line studies and mouse models, used to investigate how Cyclin D1 overexpression affects replication stress and treatment sensitivity. Findings presented suggest that ATR inhibition and PARP inhibition may be promising areas for continued investigation in Cyclin D1-overexpressing histiocytic neoplasms. This video is part of ECDGA’s mission to raise awareness, provide education and support, and encourage research related to Erdheim-Chester Disease and related histiocytic disorders. The Erdheim-Chester Disease Global Alliance is a 501(c)(3) nonprofit organization dedicated to awareness, support, education, and research for those affected by ECD. Learn more about ECDGA, educational resources, events, research updates, and support opportunities at: https://www.erdheim-chester.org/ Disclaimer: The Erdheim-Chester Disease Global Alliance (ECDGA) does not provide medical advice, diagnoses, or treatments. All content is for informational purposes only. Please consult with a healthcare provider for medical concerns.